DORYX MPC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DORYX MPC (DORYX MPC).
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
| Metabolism | Doxycycline is metabolized in the liver via glucuronidation; it is not a substrate for CYP450 enzymes. About 20-40% is excreted unchanged in urine via glomerular filtration. |
| Excretion | Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized. |
| Half-life | Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction. |
| Protein binding | Approximately 82–90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent Vd: 0.9–1.3 L/kg (50–70 L in 70 kg adult); indicates extensive tissue penetration (bone, teeth, liver, spleen, lungs). |
| Bioavailability | Oral: Approximately 85–95% (DORYX MPC formulation); absorption is minimally affected by food. |
| Onset of Action | Oral: Therapeutic concentrations achieved within 2–4 hours after first dose; clinical response typically seen within 24–48 hours. |
| Duration of Action | Approximately 12–24 hours after a single oral dose; bacteriostatic levels maintained for 24 hours with once-daily dosing. |
| Molecular Weight | 462.46 |
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No dose adjustment recommended for GFR ≥30 mL/min; for GFR <30 mL/min, consider alternative therapy or reduce dose and monitor. |
| Liver impairment | No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment. |
| Pediatric use | ≥8 years and >45 kg: same as adult; ≤45 kg: 4.4 mg/kg/day in 1-2 divided doses on day 1, then 2.2 mg/kg/day once daily; not recommended <8 years. |
| Geriatric use | No specific dose adjustment; use lowest effective dose and monitor for GI intolerance and superinfection. |
| 1st trimester | Doxycycline is contraindicated in the first trimester due to risks of fetal skeletal malformations and delayed bone growth. |
| 2nd trimester | Use is not recommended due to potential for permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also associated with reversible inhibition of bone growth. |
| 3rd trimester | Same as second trimester: contraindicated due to tooth discoloration and bone growth impairment. |
Clinical note
Comprehensive clinical and safety monograph for DORYX MPC (DORYX MPC).
| Placental transfer | Doxycycline crosses the placenta extensively, achieving fetal serum concentrations 60-70% of maternal levels. |
| Breastfeeding | Doxycycline is excreted into breast milk in low concentrations. However, due to the potential for serious adverse reactions in nursing infants, such as tooth discoloration and bone growth inhibition, breastfeeding is generally not recommended during therapy. Alternative antibiotics should be considered, especially in prolonged or repeated courses. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to doxycycline or any component of the formulationPatients with known photosensitivityPregnancy (especially second and third trimesters)Children under 8 years of age (due to tooth discoloration and bone growth impairment)
| Precautions | Photosensitivity: exaggerated sunburn reaction; avoid prolonged sun exposure., Esophageal injury: risk of esophageal ulceration; take with adequate fluids and avoid lying down after dose., Tetracycline use during tooth development (last half of pregnancy, infancy, children <8 years) may cause permanent tooth discoloration and enamel hypoplasia., Hepatotoxicity: rare but serious; monitor for symptoms., Pseudomembranous colitis: Clostridioides difficile-associated diarrhea., Intracranial hypertension: potential for bulging fontanelles in infants and papilledema in older patients. |
| Food/Dietary | Avoid dairy products (milk, cheese, yogurt) within 2 hours of dosing. Avoid iron supplements, antacids, bismuth subsalicylate, and calcium supplements within 2 hours of taking DORYX MPC. High-fat meals may delay absorption but are generally acceptable. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) - limited data suggest risk; caution advised. |
| Teratogenic Risk | Doxycycline, the active ingredient in DORYX MPC, is classified as FDA Pregnancy Category D. Use during the second and third trimesters is associated with permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Additionally, inhibition of fetal bone growth may occur. First trimester exposure has not been clearly linked to major malformations, but animal studies show fetotoxicity. Use during pregnancy is contraindicated unless no alternative therapy is available for severe infections. |
| Fetal Monitoring | In pregnant women receiving doxycycline, monitor fetal growth and development via ultrasound, particularly during the second and third trimesters. Assess for signs of hepatotoxicity in the mother (liver function tests) as tetracyclines can cause severe hepatic injury in pregnancy. Monitor maternal renal function and ensure adequate hydration to prevent nephrotoxicity. Evaluate the infant for potential dental staining and bone growth abnormalities postnatally. |
| Fertility Effects | Doxycycline may transiently impair fertility in males by affecting sperm motility and count, though these effects are reversible upon discontinuation. In females, there is no clear evidence of direct fertility impairment; however, disruption of vaginal flora may occur. Animal studies have shown doxycycline to cause reduced fertility at high doses, but clinical significance in humans is uncertain. |
| Clinical Pearls | Administer with a full glass of water to reduce esophageal irritation. Avoid giving with dairy products, antacids, or iron supplements due to chelation. Use with caution in renal impairment; adjust dosing. May cause photosensitivity; recommend sun protection. |
| Patient Advice | Take exactly as prescribed; do not skip doses. · Take with a full glass of water and remain upright for at least 30 minutes after dosing. · Avoid milk, yogurt, cheese, and other dairy products within 2 hours of taking DORYX MPC. · Use sunscreen and protective clothing to avoid severe sunburn. · Complete the full course even if symptoms improve. · Report any signs of esophageal pain or difficulty swallowing immediately. |